Session » Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2528

A Multicenter Study Assessing the Efficacy and Safety of Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: Preliminary Interim Data from the Open-Label Treatment Period

9:00AM-11:00AM: Abstract Number: 2510

A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate

9:00AM-11:00AM: Abstract Number: 2521

A Randomized, Double-Blind Phase III Study Comparing the Efficacy, Safety and Immunogenicity of PF-06438179/GP1111 (Ixifi™), an Infliximab Biosimilar, and Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Active RA: Results from Week 54 to Week 78

9:00AM-11:00AM: Abstract Number: 2531

Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2537

Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)

9:00AM-11:00AM: Abstract Number: 2511

Benepali Switches in Clinical Practice – a Positive Single Centre Experience

9:00AM-11:00AM: Abstract Number: 2522

Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)

9:00AM-11:00AM: Abstract Number: 2513

Change in Disease Activity after Switching Etanercept (originator) to Biosimilar (Benepali) Is Associated with Active Disease at Baseline

9:00AM-11:00AM: Abstract Number: 2544

Changes of CD4-(CD8+) Regulatory T Cells in Rheumatoid Arthritis Patients and during Interleukin-2 Therapy

9:00AM-11:00AM: Abstract Number: 2525

Correlation Analysis between Sirukumab Exposure and Selected Safety Events Following Subcutaneous Administration Using Pooled Phase 3 Data in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2514

Development of a Subcutaneous Formulation of CT-P13 (Infliximab): Maintenance Subcutaneous Administration May Elicit Lower Immunogenicity Compared to Intravenous Treatment

9:00AM-11:00AM: Abstract Number: 2540

Effect of Buccal Hygiene on the Systemic Activity of Patients with Rheumatoid Arthritis: A Randomized Clinical Trial

9:00AM-11:00AM: Abstract Number: 2524

Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 2520

Efficacy of the Reference Biologic Agents in Two Different Types of Randomized Clinical Trials: 1/ the Ones Comparing Their Efficacy Vs. Placebo and 2/ the Ones Comparing Their Efficacy Vs. Biosimilar in Rheumatoid Arthritis: A Systematic Review of Literature and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2519

Exposure-Efficacy Analysis in DMARD Inadequate Response Rheumatoid Arthritis Patients Treated with GSK3196165 Along with Methotrexate

9:00AM-11:00AM: Abstract Number: 2518

GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study

9:00AM-11:00AM: Abstract Number: 2541

Impact of 12-Weeks of Upadacitinib Treatment on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Dmards

9:00AM-11:00AM: Abstract Number: 2534

Impact of Block Switch to Biosimilar Etanercept in Practice, Accross Different Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2542

Integrated Exposure-Response Analyses for Upadacitinib Efficacy and Effects on Laboratory Parameters in Rheumatoid Arthritis – Analyses of Phase 2b Studies

9:00AM-11:00AM: Abstract Number: 2515

Joint Damage Progression According to Disease Activity States in Patients with Rheumatoid Arthritis Treated with CT-P10 and Reference Rituximab: Up to 48 Weeks Results from Phase III Study

9:00AM-11:00AM: Abstract Number: 2529

Liver Function Test Levels with Sarilumab Treatment in Phase 3 Trials: Analysis By Baseline Liver Function Test (LFT) Level

9:00AM-11:00AM: Abstract Number: 2516

Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol

9:00AM-11:00AM: Abstract Number: 2527

Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up

9:00AM-11:00AM: Abstract Number: 2509

Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years’ Treatment

9:00AM-11:00AM: Abstract Number: 2549

Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study

9:00AM-11:00AM: Abstract Number: 2550

Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar

9:00AM-11:00AM: Abstract Number: 2538

Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2523

Rapid Response with Upadacitinib Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Csdmards or Bdmards

9:00AM-11:00AM: Abstract Number: 2543

Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry

9:00AM-11:00AM: Abstract Number: 2526

Revealing and Addressing Knowledge Gaps Regarding Biosimilars in Rheumatology Practice with Targeted Continuing Education and Patient Surveys

9:00AM-11:00AM: Abstract Number: 2551

Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study

9:00AM-11:00AM: Abstract Number: 2535

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CKD-506, a Novel, Histone Deacetylase 6 (HDAC6) Inhibitor, in Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 2539

SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care

9:00AM-11:00AM: Abstract Number: 2533

Switching Patients with Arthritis from Etanercept (Enbrel) to the Biosimilar Drug, Benepali: A Single- Center Retrospective Observational Study

9:00AM-11:00AM: Abstract Number: 2546

The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib

9:00AM-11:00AM: Abstract Number: 2532

The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry

9:00AM-11:00AM: Abstract Number: 2548

The Impact of Rheumatoid Arthritis on Patient-Reported Outcomes: Comparison between Sarilumab Clinical Trials and Real-World Patient Data

9:00AM-11:00AM: Abstract Number: 2517

The JAK1-Selective Inhibitor Filgotinib Reverses the Disease-Associated Transcriptional Profile Found in the Blood of Patients with Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2512

Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar

9:00AM-11:00AM: Abstract Number: 2530

Uncovering Clinicians’ Gaps and Attitudes Toward Biosimilars: Impact of a 2-Phase Educational Program

9:00AM-11:00AM: Abstract Number: 2547

Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate

9:00AM-11:00AM: Abstract Number: 2545

Use of Oral Complementary Medicine in Inflammatory Arthritis: Data from the Australian Rheumatology Association Database (ARAD)

9:00AM-11:00AM: Abstract Number: 2536

Vagus Nerve Stimulation in Patients with Rheumatoid Arthritis: 24 Month Safety and Efficacy

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].